INTRODUCTION
============

Neurotransmission comprises both excitatory and inhibitory signals. Therefore, understanding the mechanisms underlying the imbalance of these signals that are found in pathologies of the central nervous systems (CNSs) are vital in pursuing specific therapeutic strategies. In inhibitory neurotransmitter systems, gamma-aminobutyric acid (GABA) A receptor (GABA~A~)-mediated synaptic transmission is particularly important because its fast, ligand-gated inhibitory conductance allows fine homeostatic tuning of excitation-inhibition balance (see review [@B61]; [@B131]).

Accumulating evidence has revealed that the function and distribution of the GABA~A~ receptor are remarkably diverse because of their subunit assembly. Some GABA~A~ receptor isoforms have been shown to be expressed outside synapses, and tonically activated by low concentrations of GABA (i.e., tonic inhibition) existing in the extrasynaptic space ([@B118]; [@B61]). Although the proportion of GABA~A~ receptor subtypes mediating tonic inhibition is estimated to be of minor abundance as compared with that mediating synaptic inhibition ([@B119]), this effect nevertheless provides strong inhibitory force by shunting the electrical signal transmission. With increased knowledge about its functional significance, an alteration in tonic inhibition has received great attention as a mechanism underlying the pathophysiology of various CNS disorders. Its distinct properties and pharmacology may thus provide new therapeutic strategies for overcoming limitations of conventional GABA~A~ receptor modulators. Thus far, deregulation of tonic inhibition has been shown to be a mechanism responsible for underlying a variety of CNS pathologies, including epilepsy, neurodevelopmental disorders, cognitive dysfunctions, and psychiatric disorders (see review, [@B25]; [@B76]).

In addition to tonic inhibition induced by GABA generated by synaptic spillover, another form of tonic conductance occurs before synaptic formation. This tonic conductance is depolarizing because the intracellular chloride (Cl^-^) concentration is high in immature neurons due to the balance of Cl^-^ transporters ([@B132]; [@B173]; for review, see [@B18]). The release of GABA in the milieu occurs via non-vesicular mechanisms ([@B48]; [@B112]; for review, see [@B133]). This tonic GABA~A~ receptor-mediated conductance is considered to be involved in a variety of developmental events, such as neurogenesis ([@B107]; [@B72]; [@B5]), migration ([@B13],[@B15],[@B14],[@B16]; [@B105]; [@B43]; [@B73]; [@B22]; [@B49]; [@B81]; [@B82]) and synaptogenesis ([@B124]; [@B164]). Based on these findings, perturbation of tonic depolarization could also result in brain mal-development.

In this review, we provide an overview on the advancement in knowledge about the role of dysregulation of tonic inhibition in the pathophysiology of various CNS diseases (with the exception of epilepsy, which will be reviewed independently in this issue), and its involvement in their therapeutic strategies. Furthermore, we review the latest findings of tonic depolarization underlying brain mal-development (with the exception of the hippocampus, which will be reviewed independently in this issue).

RECEPTOR COMPOSITION AND DISTRIBUTION OF TONIC INHIBITION
=========================================================

Gamma-aminobutyric acid A receptors are assembled from a family of 19 homologous subunit gene products (six α subunits, three β subunits, three γ subunits, three ρ subunits, and one each of the ε, δ, θ, and π subunits) and form mostly hetero-oligomeric pentamers (for review, see [@B131]). Most GABA~A~ receptor subtypes are formed from two copies of a single α, two copies of a single β, and one copy of another subunit (γ, δ, or ε). Each subunit combination has a distinct distribution pattern in terms of subcellular domains. The δ subunit, generally partnered with the α4 (forebrain predominant) and α6 (cerebellum predominant) subunits, are shown to be exclusively localized in extrasynaptic membranes in various neuronal cells, including cerebellar granule cells (CGCs), dentate gyrus granule cells, neocortical layer 2/3 pyramidal cells ([@B127]; [@B126]; [@B168]), interneurons in the neocortex and hippocampus ([@B150]; [@B95]), thalamic relay neurons ([@B39]), medium spiny neurons of the striatum ([@B1]), and dorsal horn spinal neurons ([@B21]). The δ subunit-containing GABA~A~ (δ-GABA~A~) receptor shows high affinity and slow desensitization to GABA ([@B148]), which allows tonic activation in response to low concentration of ambient GABA in extrasynaptic space (though see [@B27]).

The α5 subunit-containing GABA~A~ receptors, which presumably do not include the δ subunit, are also expressed in extrasynaptic membranes. The α5 subunit is predominantly detected in hippocampal pyramidal neurons ([@B155]), showing higher GABA sensitivity compared with α1 GABA~A~ receptors, which allows tonic inhibition in hippocampal pyramidal neurons ([@B30]; [@B67]). The α1 and α5 subunit-mediated tonic inhibition is also shown in cortical principal neurons in layer 2/3 and layer 5, respectively ([@B172]). In line with the predominant distribution of extrasynaptic α5 subunit-containing GABA~A~ receptors ([@B28]; [@B40]; [@B30]), perisynaptic α5 subunits also mediate the GABA spillover component of slow phasic inhibitory currents ([@B135]). The contribution of such a slow inhibitory synapse transmission to the signal computation may be a future issue to explore with further studies.

The other assemblies (e.g., α1γ2 subunit-containing receptor), which mainly mediate synaptic inhibition, also exist in the extrasynaptic membrane ([@B88]) and can contribute to tonic inhibition because their specific agonist, zolpidem, amplifies the tonic currents ([@B150]; [@B172]). High affinity αβ subunit-containing GABA~A~ receptors have also been shown to mediate tonic inhibition in rat hippocampal pyramidal neurons ([@B122]). Nevertheless, it is now clear that the GABA~A~ receptor subtypes having the δ or α5 subunit are the dominant forms which are responsible for mediating tonic inhibition in the mammalian brain, including humans ([@B149]).

REGULATION OF TONIC INHIBITION
==============================

After the finding of tonic inhibition in the mature brain ([@B87]), its functional significance for regulating network excitability was subsequently revealed. In CGCs, blocking tonic inhibition decreases membrane shunting ([@B24]) and increases information flow from granule cells to Purkinje cells ([@B70]). In thalamic relay neurons or hippocampal interneurons, baseline membrane potentials and network oscillation are modulated ([@B39]; [@B153]). Deregulation of tonic inhibition caused by a lack of synaptic plasticity-associated proteins has been shown in several mice models of neurological disorders ([@B41]; [@B130]; [@B56]). However, the pathophysiological significance of long-term modification of extrasynaptic GABA~A~ receptor activation can be masked by compensatory mechanisms ([@B26]; [@B170]). Some adaptive regulation responses could be attributed to the modification of GABA~A~ receptor trafficking and/or clustering on the membrane surface ([@B142]; see review [@B76]).

Progress in the development of pharmacological agents that predominantly modulate extrasynaptic GABA~A~ receptors (summarized in Table [1](#T1){ref-type="table"}) has contributed to the uncovering of the pathological significance of dysregulated tonic inhibition. Consequently, large efforts have been made to use these agents for clinical use. The negative allosteric modulator of the α5 GABA~A~ receptor, α5IA, has recently been shown to improve ethanol-induced impaired performance in healthy subjects ([@B128]). However, its use in a clinical trial was stopped due to renal toxicity ([@B8]). Another negative allosteric modulator of the α5 subunit, RO4938581, is presently under a phase 1 clinical trial for Down syndrome (the study is sponsored by Roche, and its outcomes have been made publicly available). The selective orthosteric agonist of the δ-GABA~A~ receptor, 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP, or also known as gaboxadol) was used as an hypnotic drug, reaching a phase 3 trial before its cessation because of side-effects, such as hallucination and disorientation (the study is sponsored by Merck, and its outcomes have been made publicly available). However, THIP has been recently shown to be effective against behavioral and motor dysfunction in mouse models of autism spectrum disorders ([@B129]; [@B56]). Therefore, further cumulative evidence may hopefully renew an interest in using THIP for these diseases, which have no effective therapeutic strategies.

###### 

Selective modulators for extrasynaptic GABA~**A**~ receptor.

  δ-Subunit selective                                                                                                                                                        
  ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ -----------------
  THIP (4,5,6,7-tetrahydroisoxazolo (5,4-c)pyridin-3-ol; gaboxadol)   Selective orthosteric agonist of δ-GABA~A~ receptor, a restricted analog of muscimol                   [@B94]
  AA29504                                                             Positive allosteric modulator of δ-GABA~A~ receptor, analog of Kv7 channel opener, retigabine          [@B77], [@B159]
  DS2                                                                 Positive allosteric modulator of δ-GABA~A~ receptor, poor blood--brain barrier permeability            [@B162], [@B84]
  THDOC                                                               Positive allosteric modulat,or of δ-GABA~A~ receptor, an endogenous neurosteroid                       [@B20]
  **α5-Subunit selective**                                                                                                                                                   
  RO4938581                                                           Negative allosteric modulator of α5-GABA~A~ receptor, now entering to phase1 trial for Down syndrome   [@B11]
  α5IA                                                                Negative allosteric modulator of α5-GABA~A~ receptor, development has stopped due to renal toxicity    [@B8]
  MRK-016                                                             Negative allosteric modulator of α5-GABA~A~ receptor, more potent than α5IA                            [@B10]
  L-655,708                                                           Negative allosteric modulator of α5-GABA~A~ receptor                                                   [@B9]
  SH-053-20F-R-CH3                                                    Positive allosteric modulator of α5-GABA~A~ receptor                                                   [@B65]

Because extrasynaptic GABA~A~ receptors are activated by ambient GABA in the extrasynaptic space, regulation of ambient GABA concentrations must therefore be an important factor for determining the degree of tonic inhibition. The concentration of ambient GABA has been estimated to be very low, less than 300 nM in both*in vivo* ([@B89]) and *in vitro* ([@B171]; [@B144]) conditions. A considerable part of ambient GABA may be derived from spillover from the synaptic cleft ([@B68]). Thus, presynaptic functions, such as GABA synthesis and GABA release, should also regulate tonic GABA conductance. To date, reverse mode operation of GABA transporters ([@B171]; [@B74]) and GABA release via bestrophin1 anion channel ([@B100]) have been proposed as mechanisms underlying the non-vesicular release of GABA, both of which are currently under debate ([@B51]; [@B90]).

Regardless of the source of ambient GABA, GABA transporters play a pivotal role in regulating tonic inhibition. In the rat hippocampus, presynaptically located GABA transporter 1 (GAT1) and astrocytic GAT3 (corresponding to GAT4 in mice) synergistically modulate the ambient concentration of GABA via its uptake from the extrasynaptic space ([@B57]; [@B90]; [@B154]). *In vivo* analysis has shown that neuronal GAT1 plays a predominant role under resting conditions and that the uptake of GABA by astrocytic GAT3 occurs during membrane depolarization ([@B90]). In general, GAT1 and GAT3 is expressed in presynaptic neurons and astrocytes, respectively. However, this expression pattern is not consistent throughout the brain regions. For example, thalamic GAT1 and GAT3 are exclusively expressed in astrocytes, but not in presynaptic neurons ([@B47]), and thus the regulatory mechanisms for ambient GABA in the brain can differ depending on the region. Recently, compromised function of glial GATs (associated with increased tonic inhibition), has been shown to underlie the pathophysiology of absence epilepsy ([@B38]) and prevent recovery after stroke ([@B35]). Insufficient ([@B34]) or excessive ([@B56]) amounts of GAT1 can cause cerebellar dysfunction, at least in part, to deregulation of tonic inhibition.

A Schematic drawing of the regulation of tonic inhibition with some implications for CNS disorders possibly associated with dysfunction of tonic inhibition (details will be shown below) is shown as **Figure [1](#F1){ref-type="fig"}**.

![**Regulation of tonic inhibition and CNS disorders**. Aberrant tonic inhibition is suspected to be a mechanism underlying the neuronal dysfunctions in the listed disorders based on at least one of the following: (1) a direct measurement of tonic inhibition in model animals, (2) the use of extrasynaptic gamma-aminobutyric acid A (GABA~A~) receptor selective modulators in model animals, and (3) evaluation of α5 subunit expression in living human subjects (via positron emission tomography). Colored arrows indicate the proposed protein/subunit responsible for aberrant tonic inhibition (blue, down-regulation; red, up-regulation; black, GABA signaling during synaptic transmission). Dashed arrows indicate pathways still under debate. vGAT, vesicular GABA transporter; Best-1, bestrophin-1; glu, glutamate.](fncir-07-00170-g001){#F1}

SENSORY FUNCTIONS
=================

Tonic GABA conductances exist within ascending sensory pathways on each level, including spiny neurons of the dorsal horn in the spinal cord ([@B21]), thalamic relay neurons ([@B39]; [@B137]), granule cells of the olfactory bulb ([@B97]), the brain stem auditory pathway ([@B29]), and the primary sensory cortex ([@B172]; [@B95]; [@B79]). Tonic inhibition is thought to be important for sensory processing because it reduces the impact of low frequency excitation, thereby increasing its signal-to-noise ratio.

4,5,6,7-Tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) acts as an anti-nociceptive in rodent models of acute pain ([@B59]; [@B123]; [@B21]). The anti-nociceptive effect is absent from δ- or α4-GABA~A~ receptor null mutant mice ([@B32]; [@B21]), indicating that tonic inhibition plays major roles in the regulation of acute nociception. The effects of THIP have been attributed to actions at supraspinal targets, such as thalamic relay neurons ([@B177]; [@B139]; [@B32]). Tonic GABA currents mediated by the δ subunit also exist in the spinal cord dorsal horn ([@B21]). Studies on δ subunit knock-out (KO) mice indicate that tonic inhibition likely regulates the late phase of nociceptor activity, thus corresponding to central sensitization ([@B21]). This response may result from amplification of tonic inhibition caused by activity-dependent GABA spillover or induction of neurosteroids during early phase of nociception. Nociceptor activity in early phase was shown to be comparable between wild type (WT) and δ-GABA~A~ receptor KO mice ([@B21]). Therefore, a tonic inhibition in spinal cord neurons may also contribute to regulating central sensitization and acute nociception.

In the auditory thalamus, the medial geniculate body is essential for processing acoustic information. A recent study has demonstrated that age-related loss of inhibition in this area is more dominant in tonic rather than phasic inhibition ([@B138]). Decreased expression of α4δ-GABA~A~ receptors and down-regulation of glutamic acid decarboxylase (GAD) 67 have been found to be possible mechanisms underlying this difference ([@B138]). Because the efficacy of auditory coding is directly correlated with the strength of GABAergic inhibition ([@B66]; [@B50]), enhancement of tonic inhibition was proposed to be a potential strategy against age-related decline of auditory cognition. A reduction of tonic inhibition has been reported in the auditory cortex of hearing-lesioned rat ([@B174]). In this model, GAD67 was reduced in the affected region, resulting in down-regulation of both phasic and tonic inhibition. In addition, hearing-lesioned animals displayed tinnitus with a pitch in the hearing loss range, which was eliminated by the GABA transaminase inhibitor, vigabatrin, or by reducing the uptake of GABA by the GAT1 inhibitor, NO711.

COGNITIVE DYSFUNCTION AND FUNCTIONAL RECOVERY AFTER STROKE
==========================================================

Because cognition involves a group of mental processes such as memory, attention, understanding language, and learning, numerous brain regions are thus responsible for cognitive dysfunctions. The hippocampus plays a critical role in learning and memory, and recent evidence suggests that the α5-GABA~A~ receptor is abundantly expressed in this brain region, and thus may be a therapeutic target for cognitive dysfunction ([@B155]).

Down syndrome is caused by the trisomy for chromosome 21, and is the most frequent neurodevelopmental disorder of chromosomal origin. Almost all affected individuals exhibit cognitive impairment, with specific deficits in learning and memory mediated by hippocampal dysfunctions ([@B31]). This phenotype is well replicated in the Ts65Dn mouse model of Down syndrome. The finding that low-dose picrotoxin restored hippocampal long-term potentiation in this model ([@B92]) subsequently led to the hypothesis of "excessive inhibition," and was strongly recognized to play a pathological role in this syndrome. In support of this hypothesis, Ts65Dn mice were found to exhibit increased immunoreactivity of GAD65/67 and vesicular GABA transporter (vGAT; [@B17]; [@B134]; [@B114]). Numerous studies indicate that α5-GABA~A~ receptor-mediated inhibition (mainly in the tonic form) reduces learning and memory. Mice deficient in the α5 subunit show better performance of cognitive functions compared with wild-type ([@B37]; [@B40]; [@B175]). Similarly, rodents systemically administrated with various α5 subunit-selective negative allosteric modulators displayed a facilitation in learning and memory tasks, associated with increased long-term potentiation ([@B125]; [@B9],[@B10]; [@B46]; [@B11]). Therefore, specific antagonism of the α5 subunit may be a potential therapeutic strategy against cognitive impairment in Down syndrome. Indeed, recent studies have revealed that cognitive function is ameliorated with the α5 subunit-selective negative allosteric modulators, α5IA, or RO4938581, in Ts65Dn mice without any side effects ([@B23]; [@B114]). RO4938581 is currently in clinical trials for adults with Down syndrome (the study is sponsored by Roche, and its outcomes have been made publicly available). The α5-selective negative allosteric modulators have also been shown as effective enhancers for learning and memory in other cognitive deficits induced by acute inflammation ([@B165]) or general anesthesia ([@B141]; [@B178]) in mice, and by alcoholism in humans ([@B128]; [@B8]).

In the aged brain, hippocampal tonic inhibition can regulate cognitive functions. Recent animal studies and human brain imaging of elderly individuals have indicated a strong positive correlation between hippocampal hyperactivity and cognitive impairment ([@B169]; [@B60]). In support of the "excessive excitation" hypothesis, the positive (and not negative) allosteric modulator for the α5 subunit improves memory tasks in aged rats with cognitive deficits ([@B169]; [@B93]). This hypothesis may be applied to autism spectrum disorders because antiepileptic drugs sometimes improve cognitive functions in these affected individuals ([@B53]). α5 subunit selective allosteric modulators currently in clinical trials have shown promise as a potential therapeutic strategy for cognitive deficits in various CNS diseases.

Several reports have demonstrated that the inhibitory balance between phasic and tonic inhibition shifts to tonic after cortical lesion ([@B35]; [@B79]). This shift may provide protection against cell death in the acute stage, and also prevent homeostatic plasticity during the recovery period. In a cortical stroke model, excessive tonic inhibition has been proposed as a novel pharmacological target for promoting recovery after stroke ([@B35]). Therefore, negative allosteric modulators for the α5 subunit may be effective against learning and memory deficits as well as for dysfunctions after brain injury.

PSYCHIATRIC DISORDERS
=====================

Schizophrenia is generally recognized to develop from the disruption of various kinds of neurotransmission. Dysfunction in GABAergic transmission has drawn significant attention as a mechanism underlying cognitive deficits in schizophrenia ([@B69]; [@B101]). Postmortem analyses and brain imaging of living schizophrenic subjects have revealed a deficiency in the synthesis of GABA resulting from reduced transcription of GAD67 ([@B4]; [@B161]; [@B71]; [@B176]). Results of studies investigating the expression of GABA~A~ receptor subunits in postmortem tissue have been inconsistent. The expression of α1, α2, and α5 subunits have been reported to be increased ([@B80]; [@B83]; [@B102]), decreased ([@B71]), or unchanged ([@B3]). Despite the limited number of reports investigating the expression of the δ subunit, several reports have shown decreased expression of this subunit in the prefrontal cortex ([@B71]; [@B111]). A considerable limitation of the postmortem tissue analyses in these studies is the chronic consumption of antipsychotics and/or benzodiazepines in the subjects. Furthermore, symptoms of schizophrenia dynamically change with the clinical stage. A recent study involving positron emission tomography (PET) using the highly selective α5 subunit ligand, \[11^C^\]Ro15-4513, revealed an inverse correlation between binding potential and severity of the negative symptoms in medication-free subjects ([@B7]). Therefore, this result suggests that decreased expression of the α5 subunit may be involved in the pathophysiology of schizophrenia during the negative stage. Supporting this hypothesis, use of the positive allosteric modulator for the α5 subunit has been shown to improve the hyperactivity and cognitive dysfunctions in rat models of schizophrenia ([@B44]; [@B65]). However, [@B136] have shown that a negative allosteric modulator of the α5 subunit also attenuates cognitive deficits, using a different mouse model of schizophrenia. Interestingly, the authors also showed that hyperactivity was ameliorated by both positive and negative modulators for the α5 subunit in these mice. Excitatory and inhibitory biphasic changes induced by tonic conductance have been recently shown in single neurons with depolarizing reversal potential for GABA currents ([@B153]). Therefore, an increase or decrease of tonic inhibition may result in net inhibitory effects in relevant neuronal circuits in this model. Further studies are required to validate the usefulness of α5 subunit selective allosteric modulators for the treatment of schizophrenia.

Neurosteroids, metabolites of progesterone, other sex hormones, and several stress-induced steroids are potent modulators of GABA~A~ receptors ([@B98]). In particular, the extrasynaptic δ-GABA~A~ receptor shows higher sensitivity for neurosteroids compared with synaptic GABA~A~ receptors ([@B45]; [@B156]; see review [@B25]). Therefore, dysregulation of tonic inhibition may play a pivotal role in psychiatric disorders, such as anxiety and mood disorders, which are often associated with sex hormone alterations or stress. For example, expression of the δ subunit has been shown to decrease during pregnancy due to adaptive mechanisms against large elevation of progesterone metabolites ([@B109]). The rapid decrease of neurosteroids after birth can thus induce the down-regulation of tonic inhibition, resulting in postpartum depression ([@B109]).

In a rat model of premenstrual dystrophic disorders, withdrawal of progesterone leads to anxiety and increased seizure susceptibility, associated with up-regulation of the α4 subunit ([@B152]). In contrast, increased levels of neurosteroids during physiological ovarian cycles leads to reduction of anxiety and seizure susceptibility caused by up-regulation of the δ subunit ([@B110]). This difference may thus suggest that neurosteroids can alter the effects of tonic GABA conductance by dose and/or exposure time-dependent mechanisms, thereby regulating the expression of receptor subunits. In accordance with this speculation, evaluating anxiety at puberty revealed that neurosteroids negatively modulated tonic inhibition by decreasing outward currents, via α4δ-GABA~A~ receptors ([@B151]). This regulation was shown to contribute to psychiatric disorders during puberty, such as mood swings, anxiety, and anorexia ([@B6]).

Excessive stress leads to physiological and behavioral responses resulting in numerous psychiatric disorders. The hypothalamic-pituitary-adrenal (HPA) axis plays an important role for mediating physiological responses by promoting stress-induced steroid synthesis (see review [@B96]). A recent study has demonstrated that stress-derived neurosteroid acts on δ-GABA~A~ receptors of corticotrophin releasing hormone (CRH) neurons, biphasically modulating their excitability depending on the presence or absence of stress ([@B75]). The study showed that stress decreased the activity of the outward-directed K^+^, Cl^-^ co-transporter, potassium-chloride transporter 2 (KCC2), in CRH neurons, switching tonic GABA conductance from inhibitory to excitatory and resulting in increased activity of the HPA axis and elevated levels of corticosterone ([@B75]). Because blockage of corticosterone synthesis prevents stress-induced anxiety, this positive feedback loop may be one of the mechanisms underlying stress-induced psychiatric disorders ([@B145]). Overall, emerging evidence has uncovered a bidirectional modification of tonic inhibition by neurosteroids, and thus may explain why increases in neurosteroids can lead to various types of psychiatric disorders, including depression and anxiety.

AUTISM SPECTRUM DISORDERS AND RELATED SYNDROMES
===============================================

"Autism spectrum" encompasses a wide range of disorders, which can be divided into two groups with respect to their etiology: (1) recognizably distinct syndromes caused by mutations in specific genes or chromosomal loci, and (2) more common, genetically heterogeneous subjects, referred to as idiopathic autism ([@B36]). The number of subjects in the first group is much lower than idiopathic autisms ([@B36]), however their pathophysiology can be rigorously analyzed by using a genetic mouse model.

Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by malfunction of the fragile X mental retardation 1 (FMR1) gene on the X chromosome, which encodes the FMR protein (FMRP; [@B160]). Common symptoms include intellectual disability, a distinctive physical phenotype, and autism-like behavior often associated with epilepsy. FMRP is known to regulate the mRNA transcription of various synaptic plasticity-associated proteins in concert with activation of metabotropic glutamate receptors (mGluR; [@B12]). mRNA of some GABA~A~ receptor subunits, particularly the δ subunit, are targeted substrates of FMRP ([@B117]; [@B52]). Dendritic localization of δ subunit mRNA has been shown to be regulated by mGluR activation under the presence of FMRP ([@B52]), suggesting that tonic inhibition plays an important role for the homeostatic regulation of excitation-inhibition during development. Indeed, electrophysiological analysis in FMR1 KO mice revealed that tonic, but not phasic, inhibition in subicular pyramidal neurons is significantly decreased, with decreased expression of δ and α5 subunits in this region ([@B41]). Decreased expression of the δ subunit protein has also been shown in the cortex and hippocampus of this mouse model ([@B58]). [@B130] demonstrated that FMR1 KO mice exhibit remarkably reduced tonic and phasic inhibitory currents in the amygdala principal neurons, with reduced GAD65 and GAD67 expression. This group also showed that THIP rescued neuronal hyperexcitability, *in vitro*, and ameliorated hyperexcitability, *in vivo* ([@B130],[@B129]; **Figures [2A](#F2){ref-type="fig"}--[C](#F2){ref-type="fig"}**), indicating that tonic inhibition is a potent therapeutic target for FXS. In contrast, increased GAD65 and GAD67 expression was also observed in the cortex and hippocampus of FMR1 KO mice ([@B58]; [@B2]), thus indicating regional differentiation of deregulation mechanisms of inhibition.

![**Decreased tonic inhibition in mouse models of the neurodevelopmental disorders, fragile X syndrome (FXS) and Angelman syndrome**. **(A--C)** Analyses in fragile X mental retardation 1 (Fmr1) knock out (KO) mice (FXS model). **(A)** Voltage clamp traces from principal neurons of amygdala in wild type (WT) and Fmr1 KO mice, showing impaired phasic and tonic inhibition in KO mice. **(B)** Fmr1 KO mice have higher action potential (AP) firing rates for a given depolarizing current step and a lower threshold for AP generation (middle panel), which is reverted to WT levels with THIP (lower panel). **(C)** In the open field test, THIP prevents hyper locomotor activity in Fmr1 KO mice. \**p* \< 0.05, WT control vs. Fmr KO control; \#*p* \< 0.05, Fmr1 KO control vs. Fmr KO THIP. **(D,E)** Analyses in ubiquitin-protein ligase E3A (Ube3a) KO mice (Angelman syndrome model). **(D)** Decreased cerebellar tonic inhibition in Ube3a KO mice \[black bars: 20 μM bicuculline (BIC)\]. **(E)** Ataxic gait rescued by administration of THIP (right panel) in Ube3a KO mice. **(F)** THIP (lower panels) improves clasping reflex (via the tail-suspension test) in Ube3a KO mice. **(A--C)** Adapted from [@B130],[@B129]; **(D--F)** adapted from [@B56].](fncir-07-00170-g002){#F2}

Similar presynaptic dysfunction in GABAergic neurotransmission has been proposed as a mechanism underlying the autism spectrum-related disorder, Rett syndrome. Mice lacking the causal gene, methyl CpG binding protein 2, from GABAergic neurons recapitulate phenotypes as those seen in Rett syndrome, with decreased GABA levels, reduced expression of GAD65/67, and miniature inhibitory postsynaptic current amplitudes in cortical pyramidal neurons ([@B33]). Therefore, reduction of tonic inhibition may also contribute to the pathophysiology of Rett syndrome.

Findings from our recent study have shown decreased tonic inhibition as a mechanism underlying cerebellar ataxia in the autism spectrum-related disorder, Angelman syndrome ([@B56]). This syndrome is one of the ubiquitin-proteasome pathway-associated diseases with the causal gene, ubiquitin-protein ligase E3A (*UBE3A*), encoding the Ube3a protein ([@B91]). We found that Ube3a binds to GAT1 and directly controls its degradation in the cerebellum ([@B56]). Furthermore, a surplus of GAT1 was found to decrease tonic currents of CGCs in Ube3a KO mice. Because THIP can improve cerebellar dysfunctions in this mouse model under *in vitro* and *in vivo* conditions (**Figures [2D](#F2){ref-type="fig"}--[F](#F2){ref-type="fig"}**), the reduction of tonic inhibition could thus underlie cerebellar ataxia in Angelman syndrome. Expression of GAT1 and Ube3a is increased during development ([@B158]; [@B146]). Therefore, our findings suggest that Ube3a-dependent degradation of GAT1 plays an important role for neuronal plasticity of inhibitory systems by regulating tonic inhibition. Disruption of CaMK II-mediated regulation of membrane trafficking of extrasynaptic GABA~A~ receptors may also result in decreased tonic inhibition, because deactivation of CaMK II is known to play a role in the pathophysiology of this syndrome ([@B167]). Ube3a is widely expressed in the CNS ([@B86]), thus decreased tonic inhibition may also be responsible for other symptoms, such as autistic behavior, mental retardation, and seizures. Notably, Angelman syndrome is predominantly caused by the large deletion of the relevant chromosome, 15q11-13, containing genes that encode the GABA~A~ receptor α5, β3, and γ3 subunits. Therefore, these individuals show a greater severity in phenotypes compared with individuals without the deletion ([@B106]; [@B55]). The relative expression of β3 and α5 was shown to be reduced in postmortem brain tissue from patients lacking these genes ([@B140]). Therefore, tonic inhibition may be lower in typical Angelman syndrome individuals with the large deletion of 15q11-13, which could result in the phenotypic difference in patients with or without the deletion.

Accumulating evidence has indicated that the chromosome 15q11-13 abnormalities are highly correlated with the prevalence of idiopathic autisms. Genetic multi-linkage analysis has identified GABA~A~ receptor α5 and β3 subunit genes on 15q11-13 that contribute to autism susceptibility ([@B115]). Furthermore, this region is one of the most common loci where copy number variants have been observed in idiopathic autisms. The prevalence of 15q11--13 duplications in idiopathic autisms has been estimated to be at 3% ([@B36]). Although an increased copy number of 15q11--q13 has been predicted to elevate the gene expression of GABA~A~ receptor subunits, recent *in vitro* studies using human neuronal cell lines have shown contradictory results, found to be due to impaired homologous pairing ([@B116]). Therefore, expression of GABA~A~ receptor α5 and β3 subunits is likely to be reduced in individuals with duplicated 15q11-13. Furthermore, attenuated expression of α5 and β3 subunits may be a common pathophysiological feature in idiopathic autisms without the 15q11-13 mutation. In support of this hypothesis, postmortem brain tissue analyses have reported that the expression of α5 and β3 subunits are significantly decreased (in four out of eight cases) in idiopathic autism spectrum disorders ([@B78]). Further support was shown in a PET study in which binding of \[11^C^\]Ro15-4513 was significantly lower throughout the brain, particularly in the amygdala, in adult idiopathic autism patients who did not take any neuro-modulative medications ([@B120]). However, compensatory regulation that may reduce the expression of the α5 receptor in idiopathic autism subjects cannot be excluded. Nevertheless, findings from mouse models of specific gene-associated autism spectrum disorders and brain imaging of human subjects, suggest that reduced tonic inhibition may be one of the common mechanisms underlying neuronal dysfunctions in autism spectrum disorders.

NON-SYNAPTICALLY RELEASED GABA INDUCES TONIC DEPOLARIZATION DURING CORTICOGENESIS
=================================================================================

Gamma-aminobutyric acid induces depolarization and hyperpolarization in the immature and adult brain, respectively. The GABA~A~ receptor is a Cl^-^ channel (also permeable for HCO~3~^-^), and thus the developmental switch of GABA-mediated depolarization to hyperpolarization is induced by changes in the transmembranous Cl^-^ gradient, from its efflux to influx, respectively. This change is regulated by cation-Cl^-^ cotransporters \[Na--K--Cl cotransporter 1 (NKCC1), Cl^-^ uptake; and KCC2, Cl^-^ extrusion\]. Furthermore, in immature neurons the release mechanism of GABA is non-vesicular and non-synaptic, and therefore GABA-mediated activity is generally tonic. These tonic depolarizing (and excitatory on occasion) GABA actions are necessary for neurogenesis, differentiation, migration, and synaptogenesis (**Figure [3](#F3){ref-type="fig"}**).

![**Multi-modal actions of tonic modulation of the GABA~A~** receptor during corticogenesis. In the ventricular zone (VZ) and subventricular zone (SVZ), ambient GABA affects neurogenesis. Post-mitotic neurons migrating to the cortical plate are tonically depolarized by non-synaptic and non-vesicular ambient GABA, released from tangentially migrating GABA neurons prior to forming synapses, and changing migratory pace. GABA also acts in an autocrine manner to accelerate tangential migration. Vesicular release of GABA, which remains depolarizing, may contribute to synapse formation. Following the establishment of GABAergic synapses (and prior to hyperpolarization), GABA acts as an excitatory neurotransmitter due to high intracellular Cl^-^ concentration levels, predominantly resulting from Na--K--Cl cotransporter 1 (NCC1) followed by K--Cl cotransporter 2 (KCC2). Green circle: ambient GABA. Adapted from [@B64].](fncir-07-00170-g003){#F3}

During development, GABA~A~ receptor subunits exhibit a completely different expression pattern ([@B99]; [@B63]) compared with that in the adult. At the prenatal stage and during early postnatal days, cortical neurons predominantly express α2, α3, α4, α5, β2, β3, γ1, and γ2 subunits ([@B99]). Gene transcripts of α2, α3, and α5 subunits have been detected in the developing CNS ([@B99]). At rat embryonic day 17 and 20, α4, β1, and γ1 subunit transcripts have been found to be abundant in the inner half of the germinal matrix corresponding to the ventricular zone (VZ), \[although undetectable in the intermediate zone (IZ)\], thus implying that proliferating cells may express these subunits ([@B108]).

GABA~A~ receptor-mediated signaling affects neurogenesis during development. A pioneering study by [@B107] provided evidence that GABA can affect the proliferation of progenitor cells. They showed that depolarizing GABA actions led to a decrease in both DNA synthesis and the number of bromodeoxyuridine (BrdU)-labeled cells in the rat embryonic neocortex. However, later studies have revealed that GABA also has varying effects on neurogenesis in different cell-types and/or brain regions. Using organotypic slices of mouse embryonic neocortex, [@B72] revealed that differential regulation of cell production by depolarizing GABA activity occurs in cortical progenitor cells located in different regions \[i.e., promotion and inhibition of cell division in the VZ and subventricular zone (SVZ), respectively\]. These opposing effects may be attributed to the difference in the subunits of GABA~A~ receptors or in the regional concentration of ambient GABA ([@B121]).

In the neocortex, different classes of neurons, pyramidal cortical neurons, and GABAergic interneurons, originate from different sources and have distinct migration routes. Glutamatergic pyramidal neurons radially migrate from the dorsal telencephalic VZ where they are generated via radial glial scaffolding toward the cortical plate. In contrast, GABAergic interneurons arising from the medial ganglionic eminence (MGE) tangentially migrate into the cerebral wall (for review, see [@B113]). GABA~A~ receptor signaling is well known to have distinct effects on radially or tangentially migrating neurons. [@B13] demonstrated that the GABAergic modulation of neuronal migration was strongly concentration-dependent, in which femtomolar concentrations of GABA stimulated the migration along a chemical gradient (i.e., chemotaxis) while micromolar concentrations increased random migratory movement (i.e., chemokinesis). Furthermore, both processes were shown to be mediated by an increase in intracellular calcium, suggesting that GABA mediates chemotactic as well as chemokinetic migratory responses in embryonic neocortical neurons. The effect of GABA on migration is dependent on its location and receptor. Activation of neuroblastic GABA~B~ or ρ-subunit-containing GABA~A~ receptors promotes GABA migration from the SVZ and IZ, and the activation of GABA~A~ receptors in cortical plate cells induces a stop signal ([@B14]; [@B73]; [@B49]). GABA also regulates the tangential migration of immature GABAergic cortical interneurons. After generation in the MGE, GABAergic interneurons migrate to the cortex via the corticostriatal junction (CSJ), avoiding the striatum ([@B43]). Although ambient GABA levels in the CSJ are similar to those in the MGE, the response of tonic GABA~A~ receptor to ambient GABA is likely to be enhanced in the CSJ region, suggesting that a dynamic expression of GABA~A~ receptor isoforms on MGE-derived cells promotes the cortical entry of tangentially migrating MGE-derived cells ([@B42]). When GABAergic interneurons terminate their migration in the cortex their response to ambient GABA changes to a stop signal via up-regulation of KCC2 ([@B22]).

Tonic activation of GABA~A~ receptors precedes phasic activation in early development (for review, see [@B133]), hence its possible requirement for synaptogenesis during this period ([@B48]; [@B103]). Spontaneous depolarizations of GABA would be the first excitatory drive required for activity-dependent synaptogenesis ([@B124]; [@B164]; for review, see [@B19]).

PERTURBATION OF TONIC DEPOLARIZATION MAY CAUSE BRAIN MAL-DEVELOPMENT
====================================================================

As mentioned previously in this review, tonic depolarizing responses to ambient GABA is locally controlled by uptake and/or release mechanisms allowing GABA~A~ receptor-mediated actions to control a variety of developmental events in a time- and region-specific fashion. Thus, a defect in GABA~A~ receptor-mediated multimodal functions during development can cause neuronal circuit dysfunctions hence neurological disorders. Therefore, use of GABA~A~ receptor activating drugs to enhance inhibition in the immature brain may result in unexpected deleterious effects. A growing number of studies in immature animal models have demonstrated degenerative effects of several anesthetics on neuronal structure and brain functions, such as social behaviors, fear conditioning, and spatial reference memory tasks ([@B85]; [@B104]; [@B147]). Several animal studies have demonstrated that sevoflurane ([@B147]) and isoflurane ([@B143]; [@B157]), which bind to GABA~A~ receptors, exhibit deleterious effects on neuronal survival and neurogenesis when exposed at early periods of life.

Neocortical malformations, such as polymicrogyria show the presence of cortical cells in heterotopic positions; often caused by a disruption in neuronal migration ([@B163]; [@B62]). Therefore, perturbation of the numerous functions of GABA during development may underlie the etiology of cortical malformations. Focal freeze lesion in the cerebral cortex of newborn (P0) rats was shown to produce microgyrus, a focal cortical malformation with a small sulcus and a 3- or 4-layered microgyric cortex. This defect resembles human 4-layered polymicrogyria ([@B54]), a clinical condition that results from abnormal neuronal migration. [@B166] have reported that temporally increased ambient GABA causes tonic activation of neuronal GABA~A~ receptors (possibly due to depolarization because NKCC1 is up-regulated and KCC2 is down-regulated), resulting in the modulation of intracellular Ca^2+^ oscillations. These oscillations could differentially affect the migratory status of GABAergic cells ("go") and cortical plate cells ("stop"). Therefore, immature cortical plate neurons and GABAergic neurons migrate in distinct patterns to form the microgyrus and thus, abnormally induced tonic functions of GABA could be involved in migration disorders that ultimately result in cortical malformations.

CONCLUSION
==========

This review has focused on the recent progress in understanding the impact of dysregulated tonic inhibition in CNS diseases. Accumulating evidence highlights the pathophysiological significance of dysregulated tonic inhibition in a number of neurodevelopmental disorders, psychiatric disorders, and cognitive dysfunctions (see **Figure [1](#F1){ref-type="fig"}**). In addition to pharmacological progress, animal model studies are presently opening the door for practical medicine. However, an overview of these studies also presents problems for clinical application. For example, the same phenotype may result from a decrease or increase of tonic inhibition. Therefore, the net shift from excitation to inhibition may not always occur with a modulation of tonic inhibition. This paradox is possibly due to the complexity of network regulation by tonic conductance. For example, simultaneous receptor activation in either inhibitory or excitatory neurons, or multiple mechanisms can be responsible for changing membrane properties, such as shunting inhibition and a shift in intracellular Cl^-^ concentration. Although temporal characteristics of tonic inhibition are weak, maintaining network functions can possibly regulate its strength, thus suggesting a narrow therapeutic range for such modulators. A detailed assessment of these mechanisms would therefore be needed to develop a therapeutic strategy.

This review also discussed tonic depolarization induced by ambient GABA during early development, where the release of GABA is possibly non-vesicular and occurring before synaptic organization (see **Figure [3](#F3){ref-type="fig"}**). Thus far, very few studies have addressed this series of events as a potential risk factor for CNS diseases. Therefore, research focused on the pathological effects of multimodal functions of GABA during neurodevelopment may shed light on understanding the pathology of neurodevelopmental disorders in which GABA is known to play a role, for example in schizophrenia and autism spectrum disorders.
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